Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQ-C30 and QLQ-CLL17 questionnaire.
CLL
EORTC QLQ-CLL17
QoL
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
02
07
2020
revised:
28
07
2020
accepted:
29
07
2020
pubmed:
5
8
2020
medline:
30
7
2021
entrez:
5
8
2020
Statut:
ppublish
Résumé
The quality of life (QoL) analysis is likely to differ by region, ethnicity, and questionnaires in comparison with age-matched healthy controls. The EORTC QLQ-C30 and QLQ-CLL17 questionnaire validated in regional languages were administered to 127 consecutive CLL and 100 age-matched, healthy controls at a single center from 2018 to 2019. All groups of CLL patients either on wait and watch (W&W) or on treatment had significantly impaired QoL in all functional domains including global health compared to controls (P < .0001). CLL patients had significantly higher symptom scores than controls in most domains (P < .0001, 0.03 for diarrhea). There was no difference in the QoL by age or gender. Lower socioeconomic status patients had higher financial difficulty (P = .02). Patients on CIT had the worst global health (OR 12.21 compared to patients on W&W) (P = .03). Patients on ibrutinib had less worries/fears about health and functioning than patients who were on CIT (P = .04). Quality of life is severely affected in CLL patients on W&W. Global health status and worries about future health and functioning were major concerns. Socioeconomic status but not age or gender impacted QoL. Patients on ibrutinib had better QoL than on CIT.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
755-762Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Molica S. Quality of life in chronic lymphocytic leukemia: a neglected issue. Leuk Lymphoma. 2005;46(12):1709-1714.
Shanafelt TD, Bowen DA, Venkat C, et al. The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia. Leuk Res. 2009;33(2):263-270.
Shanafelt TD, Bowen D, Venkat C, et al. Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol. 2007;139(2):255-264.
Holzner B, Kemmler G, Kopp M, Nguyen-Van-Tam D, Sperner-Unterweger B, Greil R. Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr. Eur J Haematol. 2004;72(6):381-389.
Holtzer-Goor KM, Schaafsma MR, Joosten P, et al. Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study. Qual Life Res. 2015;24(12):2895-2906.
van den Broek EC, Oerlemans S, Nijziel MR, Posthuma EF, Coebergh JW, van de Poll-Franse LV. Impact of active surveillance, chlorambucil, and other therapy on health-related quality of life in patients with CLL/SLL in the Netherlands. Ann Hematol. 2015;94(1):45-56.
http://ghdx.healthdata.org/gbd-results-tool?params=gbd-api-2017-permalink/7370f9af81d6bc6eb855f6f4b122eacf. Accessed May 30, 2020.
Tejaswi V, Lad DP, Jindal N, et al. Chronic lymphocytic leukemia: real-world data from India. JCO Glob Oncol. 2020;6:866-872.
Singh T, Sharma S, Nagesh S. Socio-economic status scales updated for 2017. Int J Res Med Sci. 2017;5(7):4.
Lad DP, Tejaswi V, Jindal N, et al. Modified CLL International Prognostic Index (CLL-LIPI) using lymphocyte doubling time (LDT) in place of IgHV mutation status in resource-limited settings predicts time to first treatment and overall survival. Leuk Lymphoma. 2020;61(6):1512-1515.
Aaronson NK, Ahmedzai S, Bergman B, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-376.
van de Poll-Franse L, Oerlemans S, Bredart A, et al. International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia. Qual Life Res. 2018;27(2):333-345.
Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the research and treatment of cancer quality of life questionnaire core 30. J Clin Oncol. 2011;29(1):89-96.
Giesinger JM, Kieffer JM, Fayers PM, et al. Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. J Clin Epidemiol. 2016;69:79-88.
Sloan JA, Frost MH, Berzon R, et al. The clinical significance of quality of life assessments in oncology: a summary for clinicians. Support Care Cancer. 2006;14(10):988-998.
Mela Osorio MJ, Pavlovsky C, Pavlovsky A, et al. Impact of ibrutinib in quality of life (QoL) in patients with chronic lymphocytic leukemia (CLL): preliminary results of real-world experience. Clin Lymphoma Myeloma Leuk. 2018;18:S218-S219.
Kipps T, Ghia P, Tedeschi A, et al. Analysis of quality of life and well-being from the randomized phase 3 study of ibrutinib versus chlorambucil in older patients with treatment-naïve CLL (RESONATE-2<sup>TM</sup>). Clin Lymphoma Myeloma Leuk. 2016;16:S46.
Mansfield C, Masaquel A, Sutphin J, et al. Patients' priorities in selecting chronic lymphocytic leukemia treatments. Blood Adv. 2017;1(24):2176-2185.